What is CASI Pharmaceuticals Inc Annual Revenue?

CASI Pharmaceuticals Inc Annual Revenue fell 15.77%, in the last year to $28.54 M. Its sector's average revenue growth for the last fiscal year was 7.48%.

What is CASI Pharmaceuticals Inc Annual Net Profit?

CASI Pharmaceuticals Inc Annual Net Profit fell 45.73% in the last year to $39.26 M. Its sector's average net profit growth for the last fiscal year was -32.59%.

What is CASI Pharmaceuticals Inc Price to Earning Ratio?

CASI Pharmaceuticals Inc Price to Earning Ratio is -0.77, which is negative.

What is CASI Pharmaceuticals Inc Stock Price?

CASI Pharmaceuticals Inc Stock Price fell 26.42% and underperformed its sector by 27.75% in the past year.

What is CASI Pharmaceuticals Inc Quarterly Revenue?

CASI Pharmaceuticals Inc Quarterly Revenue rose 94.3% YoY to $13.36 M. Its sector's average revenue growth YoY for the quarter was 5.86%.

What is CASI Pharmaceuticals Inc Quarterly Net profit?

CASI Pharmaceuticals Inc Quarterly Net profit fell 137.32% YoY to $14.37 M. Its sector's average net profit growth YoY for the quarter was -47.22%.

What is CASI Pharmaceuticals Inc Mutual Fund Holding?

CASI Pharmaceuticals Inc Mutual Fund Holding remained the same in the last quarter at 0.15%.

What is CASI Pharmaceuticals Inc Promoter Share Holding?

CASI Pharmaceuticals Inc Promoter Share Holding stayed the same in the most recent quarter at 0.74%.

What is CASI Pharmaceuticals Inc Institutional Holding?

CASI Pharmaceuticals Inc Institutional Holding remained the same in the last quarter at 17.16%.

How is the CASI Pharmaceuticals Inc today?

The CASI Pharmaceuticals Inc today is trading in the green, up by 2.09% at 1.95.

How has CASI Pharmaceuticals Inc performed historically?

The CASI Pharmaceuticals Inc is currently trading up 2.09% on an intraday basis in the past week the index fell -6.70%. The index has been down -25.29% in the past quarter and fell -26.42% in the past year. You can view this in the overview section.

CASI Pharmaceuticals Inc XNAS: CASI

CASI Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

Name: CASI Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: CASI Pharmaceuticals Inc
Rating: 0.80600
Author: Trendlyne DVM scores

Download real time

1.95 0.04 (2.09%)

New 52W Low in past week

3,881 XNAS Volume

XNAS 11 Apr, 2025 5:30 PM (EDT)

Board Meeting

The latest board meeting for CASI Pharmaceuticals Inc took place on 11 Apr 2025, for the purpose of CASI Pharmaceuticals Inc Annual General Meeting for 2024 See details

CASI Pharmaceuticals Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	30.2
PE TTM Negative PE TTM Unavailable in chosen country	-0.8
Price to Book High in industry Unavailable in chosen country	16.3
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	17.2
Revenue Growth Qtr YoY % High in industry Unavailable in chosen country	94.3
Operating Revenue growth TTM % Negative Operating Revenue growth TTM % Unavailable in chosen country	-15.8
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-137.3
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-45.7
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-137.4
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-22.8

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

14.5 / 100

Technically Bearish

17.7 / 100

1Yr Price target upside is 105%

1 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

CASI Pharmaceuticals Inc Stock Price Analysis

Day Price Range 2.1% 1 Day return Unavailable in chosen country	2 (LTP) 1.92.1 LowHigh
Week Price Range -6.7% 1 Week return Unavailable in chosen country	2 (LTP) 1.92.4 LowHigh
Month Price Range -11.8% 1 Month return Unavailable in chosen country	2 (LTP) 1.92.5 LowHigh
52 Week Price Range -26.4% 1 Year return Unavailable in chosen country	2 (LTP) 1.97.7 LowHigh

View full Share Price History

CASI Pharmaceuticals Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

CASI Pharmaceuticals Inc's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-2.6

Avg. Estimate

-2.1

Low Estimate

-2.1

High Estimate

-2.1

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 19.1% in FY25

Consensus Recommendation

1 ANALYST Recommendations

BUY

The consensus recommendation from 1 analyst for CASI Pharmaceuticals Inc is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

CASI Pharmaceuticals Inc Stock Analysis

CASI Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

CASI Pharmaceuticals Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$28.54 M	15.77%	negative	Annual Revenue fell 15.77%, in the last year to $28.54 M. Its sector's average revenue growth for the last fiscal year was 7.48%.
Annual Net Profit	$39.26 M	45.73%	negative	Annual Net Profit fell 45.73% in the last year to $39.26 M. Its sector's average net profit growth for the last fiscal year was -32.59%.
Price to Earning Ratio	-0.77	-	negative	Price to Earning Ratio is -0.77, which is negative.
Stock Price	$1.95	-26.42%	negative	Stock Price fell 26.42% and underperformed its sector by 27.75% in the past year.
Quarterly Revenue	$13.36 M	94.3%	positive	Quarterly Revenue rose 94.3% YoY to $13.36 M. Its sector's average revenue growth YoY for the quarter was 5.86%.
Quarterly Net profit	$14.37 M	137.32%	negative	Quarterly Net profit fell 137.32% YoY to $14.37 M. Its sector's average net profit growth YoY for the quarter was -47.22%.
Mutual Fund Holding	0.15 %	0%	neutral	Mutual Fund Holding remained the same in the last quarter at 0.15%.
Promoter Share Holding	0.74 %	0%	neutral	Promoter Share Holding stayed the same in the most recent quarter at 0.74%.
Institutional Holding	17.16 %	0%	neutral	Institutional Holding remained the same in the last quarter at 17.16%.

VIEW LESS

Loading data..

CASI Pharmaceuticals Inc - Company Profile

What does CASI Pharmaceuticals Inc do?

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Gross Remuneration

2024

Gross Remuneration

Year

CASI Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

New 52W Low in past week

CASI Pharmaceuticals Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

CASI Pharmaceuticals Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

CASI Pharmaceuticals Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

CASI Pharmaceuticals Inc's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

EPS is expected to grow by 19.1% in FY25

Consensus Recommendation

The consensus recommendation from 1 analyst for CASI Pharmaceuticals Inc is BUY

CASI Pharmaceuticals Inc Stock Analysis

CASI Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

Annual Revenue fell 15.77%, in the last year to $28.54 M. Its sector's average revenue growth for the last fiscal year was 7.48%.

Annual Net Profit fell 45.73% in the last year to $39.26 M. Its sector's average net profit growth for the last fiscal year was -32.59%.

Price to Earning Ratio is -0.77, which is negative.

Stock Price fell 26.42% and underperformed its sector by 27.75% in the past year.

Quarterly Revenue rose 94.3% YoY to $13.36 M. Its sector's average revenue growth YoY for the quarter was 5.86%.

Quarterly Net profit fell 137.32% YoY to $14.37 M. Its sector's average net profit growth YoY for the quarter was -47.22%.

Mutual Fund Holding remained the same in the last quarter at 0.15%.

Promoter Share Holding stayed the same in the most recent quarter at 0.74%.

Institutional Holding remained the same in the last quarter at 17.16%.

CASI Pharmaceuticals Inc - Company Profile

What does CASI Pharmaceuticals Inc do?

CASI Pharmaceuticals Inc Management structure

Dr. Wei-Wu He

Chairman of the Board and Chief Executive Officer

Dr. Alexander A. Zukiwski

Executive Vice President and Global Chief Medical Officer

Mr. Wei Zhang

Senior Vice President

Mr. Daniel Lang

Chief Financial Officer and Senior Vice President

Ms. Chunhua Wang

Chief Operation Officer

Ms. Kun Qian

Global Controller and Vice President

CASI Pharmaceuticals Inc Board of directors

Dr. Wei-Wu He

Chairman of the Board and Chief Executive Officer

Dr. Y. Alexander Wu

Independent Director

Mr. Thomas Folinsbee

Independent Director

Mr. Zhenbo Su

Independent Director

Mr. Xuebo Zeng

Independent Director

CASI Pharmaceuticals Inc FAQ

How is CASI Pharmaceuticals Inc today?